{"name":"Proto Pharma Ltd","slug":"proto-pharma-ltd","ticker":"","exchange":"","domain":"","description":"Proto Pharma Ltd is a specialty pharmaceutical company focused on developing innovative drug delivery systems. The company's lead product, Artemether Sublingual Spray, is currently in Phase 3 clinical trials for the treatment of malaria.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Artemether Sublingual Spray","genericName":"Artemether Sublingual Spray","slug":"artemether-sublingual-spray","indication":"Malaria (Plasmodium falciparum and other species)","status":"phase_3"}]}],"pipeline":[{"name":"Artemether Sublingual Spray","genericName":"Artemether Sublingual Spray","slug":"artemether-sublingual-spray","phase":"phase_3","mechanism":"Artemether is an artemisinin derivative that kills malaria parasites by generating reactive oxygen species that damage parasite proteins and membranes.","indications":["Malaria (Plasmodium falciparum and other species)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE52cHhmNFFZX1NYUG5qUncxbUVYN3g0RU5wTFQ4ams0VXZUcHZtLXdKaG5JWWVVMVZCY1dQZklNVm11TnNPeFBweFZ2dDdNWEdPMzhRNHIzTy0tWGFieExJ?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"NVCT Stock Price, Quote & Chart | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill","headline":"NVCT Stock Price, Quote & Chart | NUVECTIS PHARMA INC (NASDAQ:NVCT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxOZ1BsRHh2Sml4V29JamdzaG9WeHotbUI5Nlc0N2hPcHhiblpSUm95Q2RDN003RG5iN3FDSHVHWk9xdFd2Ynl5VjZnY0hDVGlkbzZsaFBFVW55R192RlZoQlFLek82MGxCNFV0WUE2TjExVl9nSTRxaDBfLVd0QTh1Sk1reTcxa1N4dERwQWxfaVZXWFV5WkJaOFlySG9qQWQ1Z1gwNldwYXlpMDhTNGxYMy1WOGlEYjJfWWpfdlo0dEFudWlsLTVxczY1UTdDTF9HclkyN1VyRDJQSmczV0E2b0xNMEpOZ3J1b0RUZkZwdW1qV21RSW52TWo2X3RXakY0dks3eEVB?oc=5","date":"2026-03-26","type":"regulatory","source":"BioSpace","summary":"Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan - BioSpace","headline":"Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Strom","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNb0Y0MGtNbWdQREZFS09xM1hmclJGQjlad3ByODFIMzVoOW5PUW5yT0V5ZzdUSFFLTE9McGlWWVlpNlJWNk5JY1dFUUEwX0pHc3Q2bGdxQTdybHd2eUFna1NEZ2VDNTFiTUdzQUJ6azRMTGhaS0M5Yi11LUpYQ1VVc1pFQ1FCRlFzd3JoVERSbnFtZTlxSnVr?oc=5","date":"2026-03-24","type":"pipeline","source":"BioWorld News","summary":"Qilu Pharma describes new VAV1 degradation inducers - BioWorld News","headline":"Qilu Pharma describes new VAV1 degradation inducers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQV3p0WXY5ZXdmOG1nQ0hYMFQyVWs2SDhvWjZYNm1XOGRBLXNPdzEtWGo5WTJvSVVRVi1icS05U1hQcUhGRGxGQWxxdF9qejJuWm1BYlRJT2dYaEVmTzkyclRQWllNSmVMSEZheW9TREtoQ05vTzUxQkdSSXE2UFFJOXNHSkNIU0RhU0szNVVTX1FIRU4zU1RLeWh6Q2d1LVZqRmIxNlJUZWFvSWplYWlWTjJoTW5DdnFYXy1Zc01QQzNiZmxSWVRjWU1ZQnFieE1sbDFwZG9JVGhOOVhZelpWM0ZMMXluU2VrdDBEVDliV0RyRmhZblVDREpvVkRhWGdhZTROUWZFaVlhM3FOWWJuRDZXemRkd21Tc2RDOEsxR3BHcW1saEItV1ZvUkxDendudDZBZHFwUlNCRzc2NVBCYmdrMzc?oc=5","date":"2025-08-28","type":"trial","source":"GlobeNewswire","summary":"Antisense Oligonucleotide Therapeutics Clinical Trial - GlobeNewswire","headline":"Antisense Oligonucleotide Therapeutics Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNemNNV2l3aW44dDRFWXJVU0JTZXVQQlVxQk00c25YWmlrWGR3X2pmdDR6UENDNHB2WURwU3A0eHdxSlZDeUVKSVoxOUtlUTBZQWN4RmZrSU1hLUFDSUdEc19IQkxKa3NTemhCQy1sOTJCRXY4bnV4SVloYThfUmx3Vzg0YlpPc2UtRXFLb1BjQWtoSGNf?oc=5","date":"2025-08-02","type":"pipeline","source":"BioSpectrum Asia","summary":"Australia searches for the next CSL - BioSpectrum Asia","headline":"Australia searches for the next CSL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPSlFhcVdwaFlONm5LenM3akJpY2hmc04zT3hMeWFVMm50ZTBMTWNZNlFWRFBUOUdJZ010blhQNkpKR1gzd2NwN0lDOXFRQlFQVmZZSW82aDRiYU94a3VaZDkxWWsxTWJGUEJlNnJWa1pGV2FEZkFLX3QyVWJJSDQ2ajgxZnVQY25wZnloZ3RBOVR4RGhSZ1REYjhHWGhzeTlmVjFmbEQ5b1ZSTktKQzltVDM0bHdBNm1DSEM2S1VSbEl0a0QybjUzZE5laFF2YTFqSkZNYlVrdXBKQm9lVjlZTTZiSDMwa3YzMUgwaHAxeV82LVNKZTFoZUI5ZG1NbThqUlE5bEFBUWJ6Rm5XcVV5Q2VWNl9NREdCN2lycUhOU2otUEh6NDBmSERtS3VPaENoMnI3M0tKRmxmTjg?oc=5","date":"2025-05-13","type":"trial","source":"GlobeNewswire","summary":"Metastatic Colorectal Cancer Clinical Trial Pipeline - GlobeNewswire","headline":"Metastatic Colorectal Cancer Clinical Trial Pipeline","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE1NMnhPX3FKVGlubndBd2tjYzdsdXdYc2dmNnVudFROYTBGTDBhWF8wNS1MZ0pSQzA5cVJ4SU9sT2MySGRLU2duWnNQWktueUNEeDJLX3JB?oc=5","date":"2025-01-27","type":"deal","source":"AZoM","summary":"New Partnership Delivers Unprecedented Efficiency for High-Throughput Material Discovery - AZoM","headline":"New Partnership Delivers Unprecedented Efficiency for High-Throughput Material Discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNSk81NTdlSElWYXduMUEza1hXS0dXMFFVZHY4bnlqaW5ZWU9lbkJTbjFzQ0lralVaci0yY3ZnZkJCdXZONlkxckxOenJySDFiSDlmVVNTVXF6VzZJNE5aa1p2S1otczkxUEZJT1lONmNzS3lfOE8tMEdWUGk5Q280UW9uRlE5X21Va2hxQ2pRdS1KMzVmcE1EdzFwMXFCdnd5WC1kQzZn?oc=5","date":"2024-11-13","type":"pipeline","source":"Livewire Markets","summary":"What it will take to create the next CSL or Telix Pharmaceuticals - Livewire Markets","headline":"What it will take to create the next CSL or Telix Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPTFNCUXNvcmpxdDBPQzhIUXMwWU5zNF9RMEMxRlhrYUZPWHVvX3ZoblgzNEM4cmxuNlJOa2l6dzA2WTBZNmZjWm1JczR3TFN2ZGlCMjVYMl91cEt0dVp1X21vU01kemhnSkREWG1naE9pb244RkNxOWRDZW9fQV9HbzBRczYwRV9lQzA2UWNQVmtPVWxUZjhrZkFaRUZUeGFfcUlaNmtpbkltY052enhVTlJrRVVYdWk3TjhHcGRCQ19IaVZWZ1lnZVYwUE1uUmRJTXBQNlRkNEFMWTk1bTdr?oc=5","date":"2024-09-19","type":"trial","source":"PR Newswire","summary":"Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight - PR Newswire","headline":"Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE01Z3M0cTlGVGV6WVozZmpUWXBEZERMTDRBTDlFcmJYZ09BbE9BQmhpeE9Ub1VFVm9xUW5ZdEN6aGZFMzg0eXhyYU1HMmRTWnU3OGc?oc=5","date":"2023-04-21","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Nuvectis Pharma, Inc. (NVCT) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Nuvectis Pharma, Inc. (NVCT) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQNlhNeTZYTWc1Nk1MS1h3eUtQcDRBZlJTUWljb01mZl9laDh6OHlTdVNLcWk3ellYMm1VaEliZ21yaFVFNndjR3lPS1k4d2xkeHFkTlVxZ09vcVVNc1RTWjlDV1p6NjdZckNUb3EtZ0FpeDBTUi10SWJUaWVIMWUwTjNOQ05kbHc?oc=5","date":"2020-10-29","type":"pipeline","source":"proto.life","summary":"Inside the Movement to Decolonize Psychedelic Pharma - proto.life","headline":"Inside the Movement to Decolonize Psychedelic Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQblN4eEpTcE15SDRBTm1rbnBTNVVkQW1GSGtEWWo5WkpJd1J1ZWoxTTVyNDI1NEg2am5PU1ByQUNXcl9rZkVZdlE2eVl5elBjcVJMVlhDanJqTGtvTmNRY1FoRmwydGdKaU5jOVZ1WFJxMWZOSk4ya3ZCU014UUR5bXpreDBVRDRXNVQtR29ERjg3OVVlVGRTak11XzNTRGZQWU54S0pHZ1Y2endSOHVOMjV5a1lwdEJMSy1FMzI3NA?oc=5","date":"2019-02-20","type":"pipeline","source":"The Conversation","summary":"As pharmaceutical use continues to rise, side effects are becoming a costly health issue - The Conversation","headline":"As pharmaceutical use continues to rise, side effects are becoming a costly health issue","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}